Merck & Co. Inc. (MRK) — closed signal from March 18, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 16, 2026.
Predicted vs. what happened
MRK price · publication thesis → realized outcomesplit-adjusted
$110.41 – $114.35Entry zone — fair-value band
$113.51Published — price the day we called it
$123.97Target — the price the thesis aimed for
$123.11Peak — highest point inside the window, not a realized return
$115.17Window close — end-of-window price, context only
What happened
Target reached
Hit or exceeded the predicted growth inside the window.
Peak price
$123.11
peak on April 9, 2026 — not a realized returnPeak gain
+8.5%
peak, from the publication priceWindow close
$115.17
end-of-window price, context onlyDays to target
—
Window
March 18, 2026 – June 16, 2026
The thesis — published March 18, 2026
Predicted growth
+10%
over the measurement windowTarget price
$123.97
the price the thesis aimed forEntry zone
$110.41 – $114.35
the fair-value band we waited forPrice at publication
$113.51
published March 18, 2026Confidence
76%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Merck is being considered as a short-term defensive pick because it makes steady cash and has strong products that last. New data about Gardasil supports confidence in one of its main growth drivers. This is more about a safe rebound and protecting capital than chasing a fast big gain, useful when markets feel uneven.
Primary drivers
- New Gardasil data makes the vaccine business look more reliable
- Pharma cash flow is steady, which helps in shaky markets
- Shares are positioned near a lower-price entry after weakness
- Regular earnings make big losses less likely
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.